Canntab Therapeutics (STU:TBF1) FCF Margin % : 173.33% (As of Feb. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Canntab Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Canntab Therapeutics's Free Cash Flow for the three months ended in Feb. 2023 was €-0.03 Mil. Canntab Therapeutics's Revenue for the three months ended in Feb. 2023 was €-0.02 Mil. Therefore, Canntab Therapeutics's FCF Margin % for the quarter that ended in Feb. 2023 was 173.33%.

As of today, Canntab Therapeutics's current FCF Yield % is 0.00%.

The historical rank and industry rank for Canntab Therapeutics's FCF Margin % or its related term are showing as below:

STU:TBF1' s FCF Margin % Range Over the Past 10 Years
Min: -1849.12 Med: 0 Max: 0
Current: -1849.12

STU:TBF1's FCF Margin % is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.25 vs STU:TBF1: -1849.12

Canntab Therapeutics FCF Margin % Historical Data

The historical data trend for Canntab Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Canntab Therapeutics FCF Margin % Chart

Canntab Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

May17

May18

May19

May20

May21

May22

FCF Margin %

Get a 7-Day Free Trial

-5,361.11

-1,107.55

-2,116.09

-999.54

Canntab Therapeutics Quarterly Data
	Mar18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23
FCF Margin %	Get a 7-Day Free Trial															-1,642.42	-2,010.34	-1,343.33	-323.08	173.33

Competitive Comparison of Canntab Therapeutics's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Canntab Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Canntab Therapeutics's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Canntab Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Canntab Therapeutics's FCF Margin % falls into.

Canntab Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Canntab Therapeutics's FCF Margin for the fiscal year that ended in May. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: May. 2022 )	/	Revenue (A: May. 2022 )
	=	-2.159	/	0.216
	=	-999.54 %

Canntab Therapeutics's FCF Margin for the quarter that ended in Feb. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Feb. 2023 )	/	Revenue (Q: Feb. 2023 )
	=	-0.026	/	-0.015
	=	173.33 %

Canntab Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Canntab Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Canntab Therapeutics (STU:TBF1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Canntab Therapeutics Ltd (STU:TBF1) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9

Website

https://www.canntab.ca

Canntab Therapeutics Ltd is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. It has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use.

Canntab Therapeutics (STU:TBF1) Headlines

No Headlines